Clear Labs, Inc.

Henrik Gehrmann

Sasan Amini

Ramin Khaksar

Michael Taylor

David Tran

Adam Forrest Allred

Shadi Shokralla

Sima Mortazavi

Shaokang Zhang

Kyle Rhoden

Susan Jisoon Lee

Bryan Thomas Barney

Prasanna Thwar Krishnan

Provided herein are fully-automated next-generation sequencing platforms and processes for detection of a target specimen (e.g., SARS-CoV-2) and for distinguishing infectious from non-infectious signals from the specimen. An analysis can provide simultaneous diagnosis and genomic surveillance of a multitude of distinct specimens in a sample information. The analysis can comprise distinguishing between infectious versus infectious specimens and provide a recommendation as to how infectious the sample can be. The information on can be used to better inform the status of a subject or a location with regards to infectivity from the specimen.

Systems and processes for distinguishing pathogenic and non-pathogenic sequences from specimens

Provided herein are fully-automated next-generation sequencing platforms and processes for detection of a target specimen (e.g., SARS-CoV-2) and for distinguishing infectious from non-infectious signals from the specimen. An analysis can provide simultaneous diagnosis and genomic surveillance of a multitude of distinct specimens in a sample information. The analysis can comprise distinguishing between infectious versus infectious specimens and provide a recommendation as to how infectious the sample can be. The information can be used to better inform the status of a subject or a location with regards to infectivity from the specimen.

Growing community of inventors

Newark, CA, United States of America

Henrik Gehrmann